Celldex Therapeutics
barzolvolimab
Chronic Spontaneous Urticaria
Countdown
117days
Phase 3 readout · ~ Oct 31, 2026 estimated
What's at stake
Phase 3 trial results for barzolvolimab in Chronic Spontaneous Urticaria are due ~ Oct 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT06455202: Phase 3 trial, sponsor Celldex Therapeutics, drug barzolvolimab. Primary completion date 2026-10 (estimated).”